Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MT-ATP6 pseudogene 31 (MTATP6P31) is classified as a human mitochondrial pseudogene related to the true MT-ATP6 gene, which encodes a subunit of the mitochondrial ATP synthase complex (complex V of the respiratory chain)[1][3][7]. Unlike the functional MT-ATP6 gene, which is essential for ATP production and has established pathogenic mutations causing mitochondrial diseases such as Leigh syndrome[1][5][7][8], MTATP6P31 does not encode a functional protein, is not transcribed into a functional product, and is not implicated in physiological or pathological processes. Pseudogenes are generally considered non-functional gene remnants, and there is no evidence that MTATP6P31 has any role in drug targeting, signaling, disease pathology, or as a biomarker. Any reference to this pseudogene as a drug target, receptor, enzyme, or clinically relevant molecule is not supported by current scientific or medical knowledge.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MT-ATP6 pseudogene 31 (MTATP6P31).